Geneva, Switzerland and Boston, MA -December 7, 2017 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that company management will participate in the BMO Prescriptions for Success Healthcare Conference on December 14th, 2017, in New York City.
ObsEva's presentation will take place on Thursday, December 14th, 2017, at 3.00 p.m. Eastern Time (ET). A webcast will be available in the "Investors" section of ObsEva's website www.ObsEva.com.
About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com.
###
Media Contact:
Liz Bryan
Spectrum Science
[email protected]
+1 202-955-6222 x2526
Company Contact:
CEO Office contact
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550
Investor Contact
Mario Corso
Senior Director, Investor Relations
[email protected]
+1 781-366-5726
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/c8567854-1956-4005-ac07-72b7f4767671


CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Instagram Outage Disrupts Thousands of U.S. Users
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 



